#NFX Exec Director Dan Gooding spoke with DirectorsTalk this morning summarising the Company's interim report and recent #NXP002 news tinyurl.com/2k2tukjq #ipf #ILD #curePF

The second of #NFX's patents for #NXP004 published yesterday - data suggests the proprietary drug forms described can lead to improved performance of targeted therapies for cancer patentscope.wipo.int/search/en/deta…

#NFX exec director Dan Gooding spoke with Zak Mir today on wide ranging key issues following recent news zakstraderscafe.com/dan-gooding-ce… #nfx #nuformixplc #nxp002 #cureIPF

Prof. Luca Richeldi stating yesterday at #ATS2023 that inhalation is part of a brighter future for #IPF treatment #NXP002 #NFX

#NuformixPlc is pleased appoint Kreston Reeves as auditor to the company polaris.brighterir.com/public/nuformi…

We get a lot of questions on the subiect of what causes #IPF this graphic from Pulmonary Fibrosis Foundation is a great summary. There will be a chance to ask #NuformixPIc more questions very soon #NFX #NXP002 #curePF

Another impressive regulatory approval for Lynparza in prostate cancer announced today onclive.com/view/fda-appro… #NFX #NXP004 #lynparza

📣 Today marks the start of #VolunteersWeek! We’re kicking off the week by saying a huge THANK YOU to all our APF volunteers👏 The time you give really does make a difference to the lives of people affected by pulmonary fibrosis💜 🎥 Here’s a short message from our CEO, Louise

Congratulations to Qureight on making the BusinessCloud.co.uk top 50 #medtech list for 2023 - big things to come for sure! businesscloud.co.uk/medtech-50-vot…

Looking forward to today’s Investor Q&A with #NFX Executive Director Dr Dan Gooding polaris.brighterir.com/public/nuformi…

A recording of the presentation and Q&A with Dr Dan Gooding held on 13 June is now available via the Nuformix website for those who missed it or want to watch again nuformix.com/videos/

An incredibly productive and educational #ERS2023 so far, making new connections and gaining new insights! Inhalation and combination therapies in the treatment of #IPF have to be part of the solution towards long term safety and efficacy in lung fibrosis #NFX #NX002

Pleased to announce the NXP002 Orphan Drug Designation draft application. First stage in the ODD process. Discussions with potential partners to secure an out-licence or option agreement for NXP002 continue to proceed with a number of parties. polaris.brighterir.com/public/nuformi…

Nuformix submits Orphan Drug Designation application for NXP002 in IPF. Constructive discussions continue with a number of potential out-licensing partners. polaris.brighterir.com/public/nuformi…

Nuformix announces NXP002 update describing positive results from analysis of lung tissue from IPF and autoimmune ILD patients following on-going discussions with potential partners polaris.brighterir.com/public/nuformi…

We are delighted to announce confirmation of European Orphan Drug Designation for our NXP002 programme in IPF polaris.brighterir.com/public/nuformi…